Birte Yding Glenthoej

Birte Yding Glenthoej

Auto-generated profile, based on publicly available information

Birte Yding Glenthoej

Center for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Center Glostrup, Glostrup, Copenhagen University Hospital - Mental Health Services CPH, Glostrup, Denmark

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in American Journal of Psychiatry
Verified
Journal Article
Closed access
OHOliver D. Howes
Oliver D. Howes
RMRob McCutcheon
Rob McCutcheon
OAOfer Agid
Ofer Agid
ABAndrea de Bartolomeis
Andrea de Bartolomeis
NBNico J.M. van Beveren
Nico J.M. van Beveren
CCChristoph U. Correll
Christoph U. Correll

1 March 2018 in Biological Psychiatry
Verified
Journal Article
Open access
RHRikke Hilker
Rikke Hilker
DHDorte Helenius
Dorte Helenius
BFBirgitte Fagerlund
Birgitte Fagerlund
ASAxel Skytthe
Axel Skytthe
KCKaare Christensen
Kaare Christensen
BGBirte Glenthøj
Birte Glenthøj
Twin studies have provided evidence that both genetic and environmental factors contribute to schizophrenia (SZ) risk. Heritability estimates of SZ in twin samples have varied methodologically. This study provides updated heritability estimates based on nationwide twin data and an improved statistical methodology. Combining two nationwide registers, the Danish Twin Register and the Danish Psychiatric Research Register, we identified a sample of twins born between 1951 and 2000 (N = 31,524 twin pairs). Twins were followed until June 1, 2011. Liability threshold models adjusting for censoring with inverse probability weighting were used to estimate probandwise concordance rates and heritability of the diagnoses of SZ and SZ spectrum disorders. The probandwise concordance rate of SZ is 33% in monozygotic twins and 7% in dizygotic twins. We estimated the heritability of SZ to be 79%. When expanding illness outcome to include SZ spectrum disorders, the heritability estimate was almost similar (73%). The key strength of this study is the application of a novel statistical method accounting for censoring in the follow-up period to a nationwide twin sample. The estimated 79% heritability of SZ is congruent with previous reports and indicates a substantial genetic risk. The high genetic risk also applies to a broader phenotype of SZ spectrum disorders. The low concordance rate of 33% in monozygotic twins demonstrates that illness vulnerability is not solely indicated by genetic factors.

27 July 2012 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
AHAlkomiet Hasan
Alkomiet Hasan
PFPeter Falkai
Peter Falkai
TWThomas Wobrock
Thomas Wobrock
JLJeffrey Lieberman
Jeffrey Lieberman
BGBirte Glenthoj
Birte Glenthoj
TSThe Wfsbp Task Force On Treatment Guidelines For Schizophrenia
The Wfsbp Task Force On Treatment Guidelines For Schizophrenia
These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological treatment of acute schizophrenia and the management of treatment-resistant schizophrenia.

6 December 2012 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
AHAlkomiet Hasan
Alkomiet Hasan
PFPeter Falkai
Peter Falkai
TWThomas Wobrock
Thomas Wobrock
JLJeffrey Lieberman
Jeffrey Lieberman
BGBirte Glenthoj
Birte Glenthoj
WSWfsbp Task Force On Treatment Guidelines For Schizophrenia
Wfsbp Task Force On Treatment Guidelines For Schizophrenia
These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A–F) and five levels of recommendation (1–5) (,b, World J Biol Psychiatry 9:242, see ). This second part of the updated guidelines covers long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of adults suffering from schizophrenia.

1 January 2005 in The World Journal of Biological Psychiatry
Verified
Journal Article
Open access
PFPeter Falkai
Peter Falkai
TWThomas Wobrock
Thomas Wobrock
JLJeffrey Lieberman
Jeffrey Lieberman
BGBirte Glenthoj
Birte Glenthoj
WGWagner F. Gattaz
Wagner F. Gattaz
WSWfsbp Task Force On Treatment Guidelines For Schizophrenia
Wfsbp Task Force On Treatment Guidelines For Schizophrenia
These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A–D). This first part of the guidelines covers disease definition, classification, epidemiology and course of schizophrenia, as well as the management of the acute phase treatment. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.

1 May 2012 in Biological Psychiatry
Verified
Journal Article
Closed access
MNMette Ødegaard Nielsen
Mette Ødegaard Nielsen
EREgill Rostrup
Egill Rostrup
SWSanne Wulff
Sanne Wulff
NBNikolaj Bak
Nikolaj Bak
HLHenrik Lublin
Henrik Lublin
BGBirte Glenthøj
Birte Glenthøj